Friday, August 10, 2012

SUN PHARMACEUTICALS LIMITED - FIRST QUARTER RESULTS - Q1 FY 2012 - NET SALES UP 62%; NET PROFITS UP 59%


SUN PHARMACEUTICALS LIMITED

FIRST QUARTER RESULTS

Highlights of Q1FY13
consolidated financials

Net sales/Income from operations stands at Rs. 2658 Cr, a growth of 62% over same quarter last year

Branded generic sales in India stands at Rs. 588 Cr, fell by 8% over Q1 last year. This is on account of  significantly higher sales in Q4 FY12.  Adjusting for this, growth in sales is 20%

US finished dosage sale is $ 285  million, and grew by 105% (in $ terms) over Q1 last year

International formulation sales is $ 68 million, and grew by 20% (in $ terms) over same quarter last  year

EBITDA stands at Rs 1217 Cr; grew by 122% over Q1 last year; resulting EBITDA margin is 46%, compared to 33% in Q1 last year.

• Net profit is Rs. 795 Cr, a growth of 59%; resulting net margin is 30%.

. Equity stands at Rs. 103.56 Cr. Public shareholding is 36.28%.

During the quarter, there has been a refinement in the basis of computing the cost of materials consumed and changes in inventories. Had this refinement not been carried out, the profit for the quarter ended June 30, 2012 would have been higher by Rs. 75 Cr.

Dilip Shanghvi, Managing Director, “Over the years, we have focused on building a consistent, predictable and profitable business.  The performance this quarter is once again a reflection of this strength.  The year has begun well as we have reported strong underlying growth across all our business segments.”

India Branded Generics – Building Chronic Therapy Leadership

Sale of branded prescription formulations in India is at Rs. 588 Cr, down by 8% from Q1 last year. Lower reported growth this quarter is on account of higher sales in Q4 of last year.  Adjusting for this, growth for the quarter is at 20% over comparable quarter last year.

Sun Pharma holds 4.6% market share in the Rs.65,300 Cr pharma market, as per latest AIOCD-AWACS report.  The company continues to be ranked no. 1 based on share of prescriptions with 6 classes of specialists: psychiatrists, neurologists, cardiologists, ophthalmologists, orthopedicians, and gastroenterologists. 


9 key products were launched in the first quarter.

US Formulations: Strengthening the Foundation of Generic Business

Sales in the US is $ 285 million for the first quarter of FY13, up by 105%, accounting for 57% of total sales.  Sales of Caraco increased by 185% in Q1FY13 when compared to Q1FY12.

Taro recently posted first quarter FY13 sales of $ 159 million, up 43% from the corresponding quarter last year. 

Net profit is $ 63 million.  R & D expense increased 47% to $11.5 million. 
 
Taro has shared that it remains cautious of the increasing competition and consequential erosion of volume on some of its major products.  This could result in significant challenges in maintaining its current performance.  Owing to this, coupled with the impact of some non-recurring revenues for Sun Pharma and a depreciating rupee, consolidated EBITDA and net margins for the quarter may not be sustainable.

Lipodox sales continued in the current quarter.  Remediation efforts at the Caraco facility in Detroit are ongoing.

Rest of World

Formulation sales in rest of the world markets outside of India and US accounted for $ 68 million in Q1FY13 , registering a growth of 20%. Excluding Taro sales outside US, underlying sales growth in $ terms for Sun Pharma business in these markets is 45%.

Active Pharmaceutical Ingredients (API): Strategic strength

API business continues to expand and support the strategic vertical integration objective.  A cumulative of 228 DMF / CEP applications have been made, with 162 approved so far.  External sales of API, accounting for a minority of the overall API produced, reached Rs 200 Cr in Q1FY13 registering a growth of 36% over the same quarter last year.

Research 

Consolidated R&D expense for Q1 FY13 is Rs. 139 Cr, or 5% of sales.

In the first quarter, ANDA for 1 product was filed.  After counting these, and adjusting for filings that were dropped, cumulatively ANDAs for 391 products have been filed by Sun Pharma and Taro with the USFDA (as on June 30, 2012).  ANDAs for 6 products received approvals in the first quarter, taking the total number of approvals to 256 (as on June 30, 2012).  ANDAs for 135 products now await USFDA approval, including 17 tentative approvals.

The total number of patent applications submitted now stands at 638, with 304 patents granted so far.

Business Rationalisation and Dividend

As a part of the proposed rationalization effective March 31, 2012  that was cleared by the board, the domestic formulations business will now operate within a wholly owned subsidiary of the company.  This is with a view to enhance focus on the business and allow for quicker responses to competitive market conditions.

The Board also approved an interim dividend of Rs.4.25 per Share of Re.1 each for the year ended March 31, 2012 in lieu of the dividend recommended by the Board for the year ended 31st March, 2012, earlier. 
  
52 week high/low price : 689.90/448.50

CURRENT MP : Rs.681

RESULTS TABLE FOR Q1 FY 13 : CONSOLIDATED

Income from operations
 Net sales/income from operations (Net of excise duty)
265814
Other operating income
2533
Total income from operations (net)
268347
Expenses
Cost of materials consumed
49780
Purchases of S I T
8974
 Changes in inventories of FG, WIP, SIT
-8523
Employee benefits
35122
Depreciation
8014
(Other expenses
58776
Total expenses
152143
Profit  from operations
116204
Other income
-2722
Finance costs
2121
Profit before tax
111361
Tax expense
19249
Net Profit
92112
Minority interest
12557
Net Profit  after minority interest etc
79555
Face Value (in Rs.)
1
Paid-up equity
10356
Earnings per share (after extraordinary items)
(a) Basic
7.7
(b) Diluted
7.7



 *  *  *  E  N  D  *  *  *

No comments:

Post a Comment